EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
A brief discussion of how the incremental building of scientific evidence is required for a new vaccine or drug (i.e., preclinical studies, phase 1, 2, 3 trials), the safety/efficacy evidence that is needed before licensure or acceptance, and the time and costs involved. CMV-specific challenges, the increased safety concerns around interventions during pregnancy, the lack of universal CMV screening, and the lack of CMV awareness by women and policymakers.
Presenter: Isabelle Boucoiran
Isabelle Boucoiran is a maternofetal medicine and reproductive infectious disease specialist as well as a clinician scientist.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Dr. Gantt is a Pediatric Infectious Diseases specialist, the Director of Clinical Research at CHU Sainte-Justine, and Full Professor in the Departments of Microbiology, Infectious Diseases & Immunology and of Pediatrics at the University of Montreal. Dr. Gantt’s current research focuses primarily on the development of CMV vaccines as well as newborn CMV screening programs.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Karen B. Fowler, DrPH, is a Professor of Pediatrics (Infectious Diseases) and Epidemiology at the University of Alabama at Birmingham. Her research has primarily focused on studies of maternal and congenital cytomegalovirus infections and the role of congenital CMV infection in sensorineural hearing loss in children.
ASHA DISCLOSURE:
Financial -
Nonfinancial -